Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Central Nervous System Neoplasms 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × CT-322 × Clear all
NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

NCT00768911 2010-10-27

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Unknown
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡